KLUS Pharma is the US subsidiary of Kelun-Biotech, a China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases.
Our Company
KLUS Pharma is based in Cranbury, NJ, and is the wholly-owned U.S. subsidiary of Kelun-Biotech, a corporation based in Chengdu, China.
We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.
We have a rich pipeline of small and large molecules targeting solid tumors and other indications with multiple ongoing clinical trials.
Our Approach
Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.
Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA.
Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR.
Dec 22, 2022
Merck and Kelun-Biotech announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.
Dec 14, 2022
A scientific poster of SKB264 will be presented at 2022 SABCS highlighting key data from Phase 2 TNBC study.
Nov 14, 2022
Come meet with us at BIO Partnering at JPM 2023 to learn more about our innovative pipeline!